Press releases

2020-05-13 - 18:00

Genkyotex receives approval from the ANSM to initiate a Phase 1 clinical study with high-dose setanaxib

2020-04-23 - 18:00

Genkyotex provides business update and reports cash position at March 31, 2020

2020-03-03 - 18:38

Genkyotex’s setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models

2020-02-27 - 18:00

Genkyotex announces 2019 annual financial results and provides corporate update

2020-02-06 - 20:30

Genkyotex raises €4.9 million in its rights issue

2020-02-04 - 17:45

Genkyotex announces its financial calendar for 2020

2020-01-17 - 07:00

Genkyotex launches a rights issue for a maximum amount of €6.13 million

2020-01-16 - 19:30

Genkyotex provides business update and reports gross cash position at December 31, 2019

2020-01-13 - 17:00

Half-yearly report on Genkyotex’s liquidity contract with Kepler Cheuvreux

2019-12-03 - 07:00

Genkyotex reports progress of Setanaxib phase 2 investigator initiated trials

2019-10-24 - 18:00

Genkyotex provides business update and reports cash position at September 30, 2019

2019-09-19 - 18:00

Genkyotex Announces First Half 2019 Results

2019-08-20 - 17:30

Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

2019-07-25 - 07:00

Genkyotex announces positive post-hoc analysis of PBC phase 2 trial and reports cash position at june 30, 2019

2019-07-22 - 07:00

The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831

2019-07-17 - 07:00

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

2019-07-01 - 07:00

Genkyotex’s GKT831 prevents multiple complications of portal hypertension in preclinical model

2019-06-24 - 07:00

Final Data Analysis of Phase 2 PBC Trial

2019-06-21 - 17:00

Result of the vote on the resolutions - Combined General Meeting of June 13, 2019 at 10 am (French)

2019-06-18 - 17:00

Registration Document including the Annual Financial Report 2018

2019-05-29 - 12:20

Notice of Meeting - Shareholders' General Meeting of June 13, 2019 (French)

2019-05-23 - 18:00

Genkyotex invites shareholders to annual general meeting on June 13, 2019

2019-05-21 - 07:00

Publication of GKT831 data in the Journal of Hepatology

2019-05-02 - 07:00

Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients

2019-05-01 - 18:00

Genkyotex Conference Call at 2pm Paris time on 2nd MayGenkyotex Conference Call at 2pm Paris time on 2nd May

2019-04-25 - 18:00

Genkyotex provides corporate update and reports cash position at March 31, 2019

2019-04-08 - 07:00

Genkyotex to present updated interim results from Phase 2 trial of GKT831 in primary biliary cholongitis at 2019 EASL International Liver Congress (ILC)

2019-03-29 - 07:00

Genkyotex reverse stock split takes effect

2019-03-11 - 07:00

Genkyotex Announces Completion of 24-Week Treatment Period of its Phase 2 Trial with GKT831 in PBC

2019-02-28 - 19:00

Genkyotex announces 2018 annual financial results and provides corporate update

2019-02-27 - 07:00

Launch of the reverse stock split of Genkyotex shares

2019-02-20 - 18:14

Genkyotex to Present Corporate Overview at Two Upcoming NASH Conferences

2019-02-11 - 19:00

Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology

2019-01-31 - 18:00

Genkyotex Provides Corporate Update and Reports Cash Position at December 31, 2018

2019-01-25 - 07:00

Genkyotex announces the approval of reverse stock split by its shareholders and provides business update

2019-01-03 - 07:00

Genkyotex announces its financial calendar for 2019

2018-12-19 - 07:00

Genkyotex announces an Extraordinary Shareholders’ Meeting to be held on January 24, 2019 at 10 am and confirms the key development milestone for GKT831 in PBC

2018-11-05 - 07:00

Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

2018-10-29 - 07:00

Genkyotex Announces Positive Outcome from the Independent SMB’s Third Pre-Planned Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

2018-10-24 - 18:00

Genkyotex provides corporate update and reports cash position at September 30, 2018

2018-10-15 - 07:00

Genkyotex Announces Presentation of GKT831 Efficacy Data in a Preclinical Model of Advanced Cholestatic Liver Disease at AASLD Liver Meeting® 2018

2018-10-08 - 07:00

Preclinical Efficacy of Genkyotex’s GKT831 in Prostate Cancer Presented at ESUR18 Meeting

2018-09-26 - 17:45

Genkyotex Announces First-Half 2018 Financial Results

2018-09-26 - 07:00

Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 for Primary Biliary Cholangitis

2018-09-03 - 17:45

Genkyotex Announces Positive Outcome from the Second Independent SMB Review of the Phase 2 Trial of GKT831 in PBC

2018-08-27 - 18:00

Genkyotex Announces Completion of Enrollment in Interim Analysis Cohort of Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

2018-08-20 - 20:30

Genkyotex secures an up to €7.5 million gross financing to further expand the development of its lead product

2018-07-31 - 18:00

Genkyotex Announces Investigator-Initiated Phase 2 Clinical Trial to be Conducted with GKT831 in Patients with Idiopathic Pulmonary Fibrosis

2018-07-25 - 17:45

Genkyotex Provides Update on PBC Phase 2 Trial And Reports June 30, 2018, Cash Position

2018-06-25 - 07:00

Genkyotex Expands License Agreement for Vaxiclase Platform with Serum Institute of India